(TCAF) T. Rowe Price - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US87283Q8675

TCAF: US, Large-Cap, Equity, Stocks, Blend

TCAF is an actively managed exchange-traded fund that primarily invests in a diverse range of U.S. equity securities, with a focus on large-cap companies. The funds investment strategy is geared towards capitalizing on growth opportunities across various sectors, with a notable emphasis on information technology and healthcare. As a non-diversified fund, TCAF may hold a significant portion of its assets in a limited number of securities, potentially resulting in higher volatility.

From a technical analysis perspective, TCAFs recent price action indicates a bullish trend, with the funds price trading above its 20-day and 50-day simple moving averages (SMA). The 20-day SMA at $33.62 and 50-day SMA at $32.29 suggest a positive short-term momentum, while the 200-day SMA at $33.08 indicates a longer-term uptrend. The Average True Range (ATR) of 0.41, equivalent to 1.19%, implies moderate volatility. Given the current technical setup, it is likely that TCAF will continue to trade within a narrow range, potentially consolidating its gains before breaking out further.

Fundamentally, TCAFs assets under management (AUM) stand at $4.5 billion, indicating a moderate level of investor interest. As the fund continues to invest in large U.S. companies, its performance is likely to be influenced by the overall direction of the U.S. equity market. With a focus on information technology and healthcare, TCAF is well-positioned to benefit from the growth prospects in these sectors.

Forecasting TCAFs future performance using a combination of technical and fundamental data, we can expect the fund to continue its upward trend, driven by its exposure to large-cap U.S. companies and growth-oriented sectors. A potential breakout above the 52-week high of $34.63 could signal further gains, with a potential target of $36.50. Conversely, a decline below the 50-day SMA at $32.29 could indicate a correction, with a potential support level at $31.50. As such, investors may consider accumulating TCAF on dips, with a medium-term outlook.

Additional Sources for TCAF ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

TCAF ETF Overview

Market Cap in USD 4,510m
Category Large Blend
TER 0.31%
IPO / Inception 2023-06-14

TCAF ETF Ratings

Growth Rating 49.6
Fundamental -
Dividend Rating 49.0
Rel. Strength -1.44
Analysts -
Fair Price Momentum 31.93 USD
Fair Price DCF -

TCAF Dividends

Dividend Yield 12m 0.43%
Yield on Cost 5y 0.57%
Annual Growth 5y 43.92%
Payout Consistency 100.0%
Payout Ratio %

TCAF Growth Ratios

Growth Correlation 3m 66.1%
Growth Correlation 12m 39.5%
Growth Correlation 5y 90.3%
CAGR 5y 16.08%
CAGR/Max DD 5y 0.98
Sharpe Ratio 12m 1.08
Alpha -0.72
Beta 0.877
Volatility 9.72%
Current Volume 748.4k
Average Volume 20d 732.5k
What is the price of TCAF shares?
As of June 15, 2025, the stock is trading at USD 34.18 with a total of 748,442 shares traded.
Over the past week, the price has changed by -0.06%, over one month by +2.21%, over three months by +7.35% and over the past year by +9.85%.
Is T. Rowe Price a good stock to buy?
Partly, yes. Based on ValueRay´s Analyses, T. Rowe Price (NYSE ARCA:TCAF) is currently (June 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 49.57 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TCAF is around 31.93 USD . This means that TCAF is currently overvalued and has a potential downside of -6.58%.
Is TCAF a buy, sell or hold?
T. Rowe Price has no consensus analysts rating.
What are the forecasts for TCAF share price target?
According to our own proprietary Forecast Model, TCAF T. Rowe Price will be worth about 36.2 in June 2026. The stock is currently trading at 34.18. This means that the stock has a potential upside of +6%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 36.2 6%